Last deal

$12M

Amount

Venture - Series Unknown

Stage

01.05.1998

Date

1

all rounds

$12M

Total amount

date founded

Financing round

General

About Company
Actelion Ltd is a biopharmaceutical company that develops and sells low molecular weight drugs for various medical needs.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1997

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company's main products include Tracleer, a therapy for pulmonary arterial hypertension, and Zavesca, a medication for type 1 Gaucher disease. Actelion also offers Ventavis, an inhaled treatment for pulmonary arterial hypertension. They are currently evaluating compounds for treating various diseases and have a partnership with Merck & Co for developing renin inhibitors. Actelion operates globally and has a focus on orphan diseases.
Contacts

Phone number

Social url

Similar Companies
999
Sucampo Pharmaceuticals

Sucampo Pharmaceuticals

Sucampo is a biopharmaceutical company that develops and commercializes specialized medicines for unmet medical needs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Bethesda, MD, USA

total rounds

1

total raised

$300M
Shield Therapeutics

Shield Therapeutics

Shield Therapeutics is a pharmaceutical company developing and commercializing late-stage, mineral-derived pharmaceuticals.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Weybridge, UK

total rounds

3

total raised

$37.86M
ViroPharma

ViroPharma

ViroPharma is a biopharmaceutical company that develops and commercializes products for serious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Exton, PA 19341, USA

total rounds

1
Millennium Pharmaceuticals

Millennium Pharmaceuticals

Millennium Pharmaceuticals is a biopharmaceutical company that develops and commercializes cancer medicines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Cambridge, MA, USA

total rounds

1
M&A Details
1

Acquired by

Johnson & Johnson

announced date

26.01.2017

price

$30B

Financials

Funding Rounds
1
1

Number of Funding Rounds

$12M

Money Raised

Their latest funding was raised on 01.05.1998. Their latest investor Reference Capital SA. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Reference Capital SA

Reference Capital SA

Reference Capital is a Swiss private investments advisor for European families.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Blockchain, Finance

Location

Geneva, Switzerland

count Of Investments

52

count Of Exists

17
Atlas Venture

Atlas Venture

Atlas Venture invests in biotech startups with seed and early stage venture investments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Cambridge, MA, USA

total rounds

1

count Of Investments

442

count Of Exists

146
Sofinnova Investments

Sofinnova Investments

Sofinnova Investments is a venture capital firm that specializes in funding and supporting Life Science and Technology start-ups.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Menlo Park, CA, USA

count Of Investments

236

count Of Exists

58
Co-Investors
Investors
4
3

Number of lead investors

4

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Venture - Series Unknown
No
Venture - Series Unknown
Yes
Venture - Series Unknown
Reference Capital SA

Reference Capital SA

Reference Capital is a Swiss private investments advisor for European families.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Blockchain, Finance

Location

Geneva, Switzerland

count Of Investments

52

count Of Exists

17
HealthCap

HealthCap

HealthCap is a venture capital firm that invests in life sciences globally.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Health Care, Venture Capital

Location

Stockholm, Sweden

count Of Investments

96

count Of Exists

14
Atlas Venture

Atlas Venture

Atlas Venture invests in biotech startups with seed and early stage venture investments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Venture Capital, Financial Services, Biotechnology

Location

Cambridge, MA, USA

total rounds

1

count Of Investments

442

count Of Exists

146
Acquisitions
3
Ceptaris Therapeutics acquired by Actelion Pharmaceuticals

Ceptaris Therapeutics acquired by Actelion Pharmaceuticals

acquirer

Actelion Pharmaceuticals
Actelion Pharmaceuticals

date

31.07.2013

type

Acquisition

price

$250M
Ceptaris Therapeutics

Ceptaris Therapeutics

Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for early-stage mycosis fungoides.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Malvern, PA 19355, USA

total rounds

10

total raised

$64.79M
Cotherix acquired by Actelion Pharmaceuticals

Cotherix acquired by Actelion Pharmaceuticals

acquirer

Actelion Pharmaceuticals
Actelion Pharmaceuticals

date

20.11.2006

type

Acquisition

price

$420M
Cotherix

Cotherix

CoTherix develops biopharmaceutical products for chronic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

total rounds

2

total raised

$55M
Axovan acquired by Actelion Pharmaceuticals

Axovan acquired by Actelion Pharmaceuticals

acquirer

Actelion Pharmaceuticals
Actelion Pharmaceuticals

date

01.10.2003

type

Acquisition
Axovan

Axovan

Axovan AG is a Swiss drug development company that specializes in G Protein-Coupled Receptors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

4123 Allschwil, Switzerland

total rounds

3

total raised

$18.3M

People

Founders
4
Jean-Paul Clozel
Jean-Paul Clozel

Jean-Paul Clozel

Jean-Paul Clozel is the CEO at Idorsia.

current job

Idorsia
Idorsia

count Of Investments

2

Jean-Paul Clozel

Walter Fischli
Walter Fischli

Walter Fischli

Dr. Walter Fischli was educated as a biochemist at the Swiss Institute of Technology (ETH) Zurich, with further training at the Addiction Research Foundation/Stanford University in Palo Alto, USA. During his subsequent 15 years at F. Hoffmann-La Roche Ltd, he worked in research and led various drug discovery projects. In 1993 he received the Hoffmann-La Roche Research Prize. In 1997, Walter co-founded Actelion Pharmaceuticals Ltd, where he built up the Biology department and complemented the other two drug discovery departments around Medicinal Chemistry and Pharmacology headed by Thomas Weller and Martine Clozel, respectively. In Mid 2009 he handed over his position to Beat Steiner and served as Senior Vice President, for Academia Relations until his retirement at the end of 2012.

current job

Actelion Pharmaceuticals
Actelion Pharmaceuticals

organization founded

1

Walter Fischli

Thomas Widmann
Thomas Widmann

Thomas Widmann

A cardiologist educated at Heidelberg and Paris in Medicine and Computer Science with further training at the University Hospital in Geneva, Thomas Widmann later spent seven years at the University of California, San Diego, as Assistant Professor of Medicine and Cardiovascular Associate. During his nine years at F. Hoffmann-La Roche, he was responsible for the worldwide clinical development of the company's cardiovascular portfolio, which included eight large projects at various stages of development (Phase I to NDA). He was chairman of F. Hoffmann-La Roche's cardiovascular strategy team and led an international cardiovascular development team of over 60 people in Europe and the US. In 1996, he founded Hesperion, a company that focuses on clinical development and consulting. Due to his continuing interest in strategic R&D and other management topics, he has also attended business courses at INSEAD. As founding member of Actelion, he was Actelion`s first Chief Executive Officer and then held the position of Vice Chairman of the Board until spring 2003. Tom continues to work in close association with the Actelion senior management.

current job

Wellington Partners
Wellington Partners

Thomas Widmann

André J. Mueller
André J. Mueller

André J. Mueller

With two degrees in Chemical Engineering and Business Administration from INSEAD, André Mueller started his career with CIBA Ltd and Sandoz (now Novartis), where he held a number of managerial positions in the strategic planning and finance divisions both at headquarters and in the US.After seven years with Sandoz, André moved to Biogen, becoming VP of Finance and Administration and then CFO. As CFO he was responsible for several financing rounds, including Biogen's IPO. Four years later, he became a Founding Partner and Director of Investments for Genevest, the first Swiss venture capital organization.In 1997, André was a member of the founding team of Actelion and served as CFO until 2003.

current job

Biogen
Biogen

count Of Investments

1

count Of Exists

1

André J. Mueller

Employee Profiles
301

Sarah Moore

Product manager

Susan Wu

Executive assistant, head of legal, hcc officer and regulatory leaders

Andrea Galli

Global director customer engagement excellence

Eddie De La Maza

Business director, south region

Alan Han

District sales leader - midwest

Debbie Quinn

Clinical science program head

Pär Stierngranat

Interim finance director nordics

Anders Lindén

Director business development

Activity

Recent News
2